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Colleen Delaney,7 Philip McCarthy,8 Edward D. Ball,9 Ram Kamble,10 David Avigan,4
Richard T. Maziarz,11 Vincent T. Ho,3 John Koreth,3 Edwin Alyea,3 Robert Soiffer,3
John R. Wingard,5 Vicki Boussiotis,4 Thomas R. Spitzer,1 Joseph H. Antin3Transplantation of 1 or 2 umbilical cord blood products is a useful alternative stem cell source. However, the
limited number of stem cells in each infusion results in slow engraftment. In mouse models, administration of
parathyroid hormone (PTH) is an effective way to enhance the ability of limited numbers of hematopoietic
stem cells to support hematopoiesis. In this study, patients received either a myeloablative or a reduced-
intensity double umbilical cord blood transplantation, followed by PTH at 100 mg/day for 28 days. Thirteen
patients (median age, 42 years) were enrolled. All patients engrafted; the median time to neutrophil and
platelet engraftment of .20  109 cells/L was 30 days and 61 days, respectively. The incidence of grade
II-IV acute GVHDwas 38.5% at day 100. Four deaths occurred before day 100, prompting early study closure.
No patient who received a myeloablative regimen relapsed. Overall survival at 6 months after transplantation
was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no
evidence that PTH influenced blood count recovery.
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[1]. Inmousemodels, theScadden laboratoryhas shown
that activation and stimulation of osteoblastic cells with
parathyroid hormone (PTH) or PTH-related protein
(PTH-rP), through the PTH/PTHrP receptor (PPR),
influences hematopoietic stem cell numbers and
function to the extent that hematopoietic function can
be restored from infusion of even limited numbers of
stem cells [2-4]. This occurs at least in part through
the Notch signaling pathway via the Notch ligand
Jagged-1 [5]. Activation of the PPRon osteoblastic cells
increases expression of the Notch ligand [5].
Based on promising data in mouse models, we
conducted a Phase I study of PTH in patients with
lymphoma or myeloma who had failed chemotherapy
and/or growth factor mobilization [6]. PTH was well
tolerated up to doses of 100 mg daily, and there was
no dose-limiting toxicity (defined as serum calcium
level .11.5 mg/dL, ionized calcium level .1.5 mM,
systolic blood pressure \80 mm Hg, or phosphate
level \1.0 mg/dL). Stem cell mobilization was suc-
cessful in 47% of the patients who had failed 1 previous
mobilization (peripheral blood with .5 CD341 cells/
mL) and in 40% of those who had failed 2 previous
mobilizations.
Umbilical cord blood (UCB) transplantation
(UCBT) is a setting in which limiting numbers of1851
1852 Biol Blood Marrow Transplant 18:1851-1858, 2012K. Ballen et al.hematopoietic stem cells are often used. Even with the
use of 2 UCB units, engraftment and immune recon-
stitution can be slow, contributing to an elevated risk
of infection and second malignancy [7-10]. Various
ex vivo expansion strategies have been studied in
efforts to improve these results, but improved
survival has not been documented [11-13].
Given that PTH administration was able to facili-
tate hematopoietic reconstitution when limiting doses
of hematopoietic stem cells were administered tomice,
we hypothesized that a similar effect might be ob-
served after UCBT. Thus, based on data demonstrat-
ing the safety of PTH administration in our previous
autologous stem cell transplantation trial, we per-
formed a Phase II study of PTH after double UCBT
as an approach to enhance hematopoietic recovery in
a clinical setting of low stem cell numbers. Although
we could not reproduce the PTH dosing used in the
previous murine experiments, we selected a dose of
100 mg/day, which was well tolerated in our Phase I
study of mobilization and could be given once daily
as 5 s.c. injections [14,15].PATIENTS AND METHODS
Patients
Patients age 18-65 years with acute leukemia in first
complete remission with high-risk cytogenetics or sec-
ond or subsequent remission, relapsed chemotherapy-
sensitive Hodgkin or non-Hodgkin lymphoma,
myelodysplasia, aplastic anemia, myelofibrosis, chronic
myelogeneous leukemia in accelerated or second stable
phase, advanced chronic lymphocytic leukemia, or
multiple myeloma were eligible for this study. Patients
with a serum calcium level.10.5 mg/dL or a phosphate
level \1.6 mg/dL were excluded. Other eligibility
criteria included Eastern Cooperative Oncology Group
performance status of 0, 1, or 2; creatinine\2.0; biliru-
bin\2.0; ejection fraction.50%; and diffusion capacity
of the lung for CO $50% of predicted. All subjects
signed an informed consent form for this clinical trial,
which was approved by the Institutional Review Boards
of both Dana-Farber/Harvard Cancer Center and the
University of Florida.Treatment Plan
Patients under age 50 years were eligible to receive
amyeloablative conditioning (MAC) regimen of cyclo-
phosphamide 1800 mg/m2/day on days 25 and 24
(total dose 3600 mg/m2); fludarabine 25 mg/m2/day
on days26,25, and24 (total dose 75mg/m2); and to-
tal body irradiation 1400 cGy in 7 divided fractions
(days 23, 22, 21, and 0). The study was later
amended to include a reduced-intensity conditioning
(RIC) regimen for patients up to age 65, whichconsisted of fludarabine 30 mg/m2/day on days 28
to 23 (total dose 180 mg/m2), melphalan 100 mg/m2
on day 22, and rabbit antithymocyte globulin (ATG)
1.5 mg/kg/day on days 27, 25, 23, and 21 (total
dose 6.0 mg/kg) as described previously [9,10]. All
subjects received commercial human PTH 1-34
(teriparatide) 100 mg/day given as 5 s.c. injections
(each dosing pen contains 20 mg per injection) on
days 1-28 of the study or until neutrophil
engraftment (absolute neutrophil count .0.5  109
cells/L). Patients received filgrastim from day 15
after UCBT until neutrophil engraftment. Graft-
versus-host disease (GVHD) prophylaxis was com-
posed of tacrolimus (starting dose, 0.05 mg/kg orally
or i.v.), adjusted to maintain a serum trough level of
5-10 ng/mL, and mycophenolate mofetil at a dose of
15 mg/kg i.v. starting on day 23 before transplanta-
tion. In the absence of GVHD,mycophenolate mofetil
was tapered after day160 with the goal of discontinu-
ation by day 1100 after transplantation, and tacroli-
mus was tapered after day 1100 with the goal of
discontinuation by 6-9 months after transplantation.
UCB Units
UCB units were obtained from national and
international UCB banks. Each patient received 2
UCB units. UCB units were required to be a 4/6
HLA-A, -B, and -DR match with the patient and
with each other, and to provide a minimum cell dose
of .3.7  107 total nucleated cells (TNCs)/kg com-
bined before cryopreservation. Typing for HLA-A
and -B was performed at molecular intermediate
resolution, and typing for HLA-DR was done at the
allele level. Each individual UCB unit cell dose
was .1.5  107 TNCs/kg before cryopreservation.
On day 0, UCB units were thawed according to the
methods of Rubinstein et al. [16] and infused sequen-
tially within 2-5 hours of one another. The UCB
unit with the higher TNCs/kg before cryopreservation
was infused first.
Definitions of Toxicity and Response
Calcium, phosphate, ionized calcium, and albumin
were monitored thrice weekly to determine any addi-
tional PTH-associated toxicity. Neutrophil engraft-
ment was defined as the first of 3 consecutive days
with neutrophil recovery to at least 0.5  109 cells/L.
Platelet engraftment was defined as the first day of an
unsupported platelet count .20  109 cells/L (with
no platelet transfusion within 7 days). Early graft fail-
ure was defined as lack of neutrophil engraftment by
day 142 after transplantation. Late graft failure was
defined as the presence of neutrophil engraftment by
day 142, followed by decline of neutrophil count
to\0.5  109 cells/L after day 142 and loss of donor
chimerism. GVHD was graded according to the
Table 1. Baseline Patient and Unit Characteristics
Characteristic Value
Race, n (%)
White 10 (76.9)
Asian 1 (7.7)
Other 2 (15.4)
Hispanic ethnicity, n (%) 4 (30.8)
Age at transplantation, years, median (range) 39 (25-67)
Primary disease, n (%)
MDS 2 (15.4)
Aplastic anemia 2 (15.4)
Hodgkin’s disease 1 (7.7)
Chronic lymphocytic leukemia 1 (7.7)
Acute myelogenous leukemia 5 (38.5)
Acute lymphoblastic leukemia 2 (15.4)
ECOG performance status at transplantation, n (%)
0 4 (30.8)
1 8 (61.5)
2 1 (7.7)
HLA match, recipient to unit 1 and unit 2, n (%)
4/6, 4/6 10 (76.9)
4/6, 5/6 1 (7.7)
5/6, 5/6 2 (15.4)
HLA match, unit 1 to unit 2, n (%)
4/6 10 (76.9)
5/6 3 (23.1)
Combined postthaw cell dose, median (range)
Total nucleated cells,  107/kg 4.2 (3.4-6.6)
CD34 cells,  105/kg 2.1 (0.4-9.0)
Conditioning regimen, n (%)
MAC 9 (69.2)
RIC 4 (30.8)
ECOG indicates Eastern Cooperative Oncology Group.
Biol Blood Marrow Transplant 18:1851-1858, 2012 1853Parathyroid Hormone and Cord Blood Transplantationconsensus criteria [17]. Donor chimerism was deter-
mined from peripheral blood samples at 2, 4, 8, and
12 weeks and 6, 12, and 24 months. Chimerism assays
were performed by short tandem repeat analysis [9].
Statistical Analysis
The primary objective was to evaluate the time
to neutrophil engraftment among patients receiving
PTH after double unrelated UCBT. The target
sample size of 40 had the power to allow us to
observe a 30% reduction in the median time to neu-
trophil engraftment using a historical median time of
23 days in our institution, with 80% power and
a one-sided significance level of 10%. The occurrences
of neutrophil engraftment, platelet engraftment, acute
GVHD, chronic GVHD, and relapse were calculated
using the cumulative incidence function, treating
death as the competing risk [18]. The probability of
overall survival (OS) was calculated using the
Kaplan-Meier estimator [19]. Death from any cause af-
ter transplantation was considered the event, with pa-
tients censored at the date of last follow-up. Analyses
were performed using SAS version 9.2 (SAS Institute,
Cary, NC) and R version 2.8.1 (The R Foundation
for Statistical Computing v2.8.1, Vienna, Austria).
Immune Reconstitution Studies
T cell receptor excision circle (TREC) analysis was
performed as described previously [20]. DNA was iso-
lated from peripheral blood mononuclear cells using
the QIAamp DNA Mini Kit (Qiagen, Valencia, CA).
Quantitation of signal-joint TCR excision circle
(sjTREC) DNA was done by Taqman real-time PCR
using an ABI Prism 7000 quantitative PCR machine
(Applied Biosystems, Foster City, California). Quanti-
tation of the sjTREC copy number for each patient
sample was performed as described previously [21], us-
ing a standard curve prepared with 10-fold dilutions of
a plasmid containing the sjTREC sequence (kindly
provided by Dr. Daniel Douek, National Institute of
Allergy and Infectious Disease Bethesda, MD).RESULTS
Patient Characteristics
Patient and UCB characteristics are outlined in
Table 1. Thirteen patients were enrolled before the
trial was halted, owing to early deaths that were con-
sidered unrelated to PTH. The median patient age
was 42 years (range, 25-67 years). Nine patients re-
ceived the MAC regimen, and 4 patients received the
RIC regimen. The majority of patients (77%) had
a 4/6 HLA-A, -B, and -DR match with both UCB
units. The median infused (postthaw) TNC dose for
the combined units was 4.2  107/kg (range, 3.4-6.6  107/kg). The median infused (postthaw)
CD341 cell dose for the combined units was
2.1  105/kg (range, 0.4-9.0  105/kg).Toxicity
The trial was halted because of excess early mortal-
ity after 4 patients died before day 1100, triggering
a review by the Data Safety Monitoring Board. Three
stopping rules were in place. The first stopping rule,
which required closure for graft failure, was not
reached. All patients who survived achieved engraft-
ment by day 142. The second rule, which also was
not reached, called for early study closure if 3 or
more patients developed grade III-IV GVHD. There
were 2 patients with grade III-IV GVHD. The third
stopping rule mandated a review after 4 patients died
of transplantation-related mortality (TRM) within
the first 100 days after transplantation. The causes of
death were polymicrobial sepsis on day 124, hepatic
venoocclusive disease on day 135, respiratory syncy-
tial virus and aspergillus pneumonia on day 125, and
polymicrobial sepsis, liver, and respiratory failure on
day 159. Autopsy in the latter case revealed pneumo-
nia, veno-occlusive disease of the liver, and GVHD.
Three of the 4 early deaths occurred in patients who
had received the MAC regimen. Importantly, none
of the deaths was considered likely related to PTH,
but given the early stopping rule and after discussion
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1854 Biol Blood Marrow Transplant 18:1851-1858, 2012K. Ballen et al.with the Data Safety Monitoring Board, the study was
closed to accrual after 13 patients were treated. Two
additional patients had provided consent but had not
yet started treatment and did not receive PTH. Addi-
tional toxicities were seen in 4 patients with a syndrome
of fever, rash, and diarrhea within the first 2 weeks after
transplantation, considered consistent with an im-
mune reaction, as described by other centers [22].
One patient was treated with topical steroids. Three
of the 4 patients had complete resolution of symptoms,
and 1 patient experienced progression of rash to acute
GVHD. No hypercalcemia or other toxicities consid-
ered related to PTH were reported.
Engraftment of Neutrophils and Platelets
Patient outcomes are illustrated in Table 2. En-
graftment of neutrophils to at least 0.5  109 cells/L
occurred at a median of 30 days after UCBT (range,
19-37 days). The incidence at day 42 was 76.9%
(95% CI, 47.3%-100%) (Figure 1). There were no
cases of graft failure among the patients who survived
to day 142. The 3 patients who died before day 142
had not yet engrafted neutrophils. Analysis of donor/
host engraftment in the peripheral blood showed the
first unit infused to be the predominant dominating
unit in 50% of patients by day 114 and in 67% of
patients by day 1100. Engraftment to a platelet
count .20  109 cells/L occurred at a median of
61 days (range, 33-76 days) and with an incidence
of 46.2% (95% CI, 17%-76%) at day 1180. Engraft-
ment to a platelet count .50  109 cells/L occurred
in 4 patients at days 149, 162, 168, and 168, with
a cumulative incidence at day 180 of 30.8% (95%
CI, 4%-58%).
GVHD and Relapse
The incidence of grade II-IV and grade III-IV
acute GVHD at day 100 was 38.5% (95% CI,
10.3%-66.7%) and 15.4% (95% CI, 0.0%-36.2%).
Three patients had grade II acute GVHD, and 2 pa-
tients had grade III-IV acute GVHD. Five patients de-
veloped chronic GVHD (all limited), with an
incidence of 38.5% (95% CI, 8.1%-68.9%) at 2 years.
Three patients, all of whom received RIC condition-
ing, relapsed at days 1101, 1214, and 1751. The
incidence of relapse at 2 years was 15.4% (95% CI,
0-36.2%). There were no relapses in the patients
who received the MAC regimen.
OS and DFS
With a median follow-up of survivors of 733 days
(range, 720-768 days), the OS probability was 61.5%
(95% CI, 30.8%-81.8%) at 6 months and 38.5% (95%
CI, 14.1%-62.8%) at 2 years (Figure 2A). The DFS
probability was 61.5% (95% CI, 30.8%-81.8%) at 6
months and 38.5% (95% CI, 14.1%-62.8%) at 2 years
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Figure 1. Neutrophil and platelet engraftment.
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as reported earlier. Four patients died after day1100, 2
of relapsed disease, 1 of diffuse alveolar hemorrhage,
and 1 of CNS infection with the JC virus. DFS pro-
bability at 2 years was 25.0% (95% CI, 0.9%-66.5%)
in the patients who received the RIC and 44.4% (95%
CI, 13.6%-71.9%) in those who received the MAC.
Immune Reconstitution
Immune reconstitution studies were performed in
7 patients. To examine immune reconstitution, weOverall Survival
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Figure 2. OSevaluated recovery of thymic function by assessing
TRECs. TRECs are useful for evaluating the de
novo production of T cells originating from newly en-
grafted stem cells. Before transplantation, the median
TREC value was within the normal range for this age
group, at 52,475 copies/mg. After transplantation, me-
dian TREC values fell significantly but was below the
limit of detection at only 8 weeks after transplantation
(Figure 3). Average TREC values reached the lower
limit of normal range (819 copies/mg) at 6 months,
and returned to the normal range by approximately Disease-Free Survival
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Figure 3. TREC levels. TREC counts per microgram of peripheral
blood mononuclear cell DNA were determined by quantitative PCR.
The line connects the average values of the individual time points. The
limit of detection of the TREC assay was 10 copies/mg DNA. The dashed
line on the far right shows the range of values for 10 normal controls of
similar ages.
1856 Biol Blood Marrow Transplant 18:1851-1858, 2012K. Ballen et al.1 year after transplantation. This return of TREC
levels is in contrast to findings from previous studies
at our center in double UCBT patients receiving the
same RIC regimen but without PTH, which demon-
strated TREC levels of 0 copies/mg at 100 days and
74.9 copies/mg at 6 months [21]. The rapid kinetics
of TREC reconstitution in the patients who received
PTH was not observed in those previous studies.
CD4 counts at day 1100 were also higher in the
PTH-treated patients compared with our historical
control population (142 cells/mL versus 86 cells/mL).DISCUSSION
We undertook this study because delayed engraft-
ment and poor immune reconstitution remain signif-
icant causes of mortality after double UCBT in
adults. The optimal strategy for enhancing the kinet-
ics of myeloid recovery and immune reconstitution
remain unclear; however, preclinical data suggest
that PTH might enhance hematopoietic recovery in
the setting of limited stem cell doses by stimulating
an in vivo increase in the number of hematopoietic
stem cells as a result of increased osteoblastic expres-
sion of the Notch ligand Jagged-1 and consequent
activation of Notch1 signaling [2]. The Seattle group
has successfully used immobilized Notch ligands for
the ex vivo expansion of UCB progenitor cells to
enhance neutrophil recovery after an MAC regimen
[12]. In our study, an early-stopping rule was met
based on early TRM, and accrual was stopped early.
No clear pattern of toxicity was apparent, with
the patients dying of common transplantation
complications, and there was no evidence that PTH
contributed to the early TRM. The decision to
halt the study was also supported by the lack of
a positive PTH effect on engraftment in the first 13
patients.Studies in mouse models contribute to the under-
standing of the importance of the osteolineage cells
in the regulatory stem cell niche. Increasing osteoblas-
tic cell activity by PPR stimulation affects hematopoi-
etic stem cell number and function [23]. Jung et al. [24]
demonstrated that PTH increases the expression of
bone marrow stromal cell-derived factor 1, possibly
leading to increased homing of stem cells. However,
in this limited sample size, the neutrophil engraftment
did not appear to be enhanced, and in fact, might even
have been delayed, compared with our historical con-
trol of 23 days. This lack of effect might have been sec-
ondary to a lack of biological activity of the PTH, the
small sample size, or inability to administer equivalent
doses to humans that were effective in mice [25]. Con-
version of the dose and type of hormone used in mice
to humans is difficult, owing to differences in sensitiv-
ity to PTH. Mice and rats can tolerate larger doses of
PTH than humans, and these high peptide doses pro-
duce dose-dependent improvements in bone mass and
bone strength inmice and rates that exceed the benefits
produced by exogeneous or endogeneous PTH in hu-
mans [26,27]. We chose a dosage of 100 mg/day based
on safety data from a Phase I study on mobilization, as
well as a desire to limit the number of injections to 5
daily injections (each dosing pen contains 20 mg
per injection) [6]. However, the study was hampered
by a lack of previous Phase I data for PTH dose esca-
lation after double UCBT. The Food and Drug
Administration–approved dose of PTH is 20 mg/day,
and large osteoporosis studies in men and postmeno-
pausal women have used doses of 20-40 mg/day
[28-30]. Side effects reported in those studies
included elevated serum calcium, headaches, joint
pain, muscle aches, and fatigue. The dose for the
current study of 100 mg might be too low to obtain
the effect seen in mice with respect to enhanced
engraftment, and whether the appropriate dose and
delivery method were identified in the setting of
UCBT is unclear. In addition, the kinetics of the
effect of PTH may differ between mice and humans,
and a meaningful change in the microenvironment
may be achieved only after longer exposure to PTH.
Immune reconstitution remains a major limita-
tion of UCBT. We performed TREC analysis to
evaluate the de novo production of T cells originating
from newly engrafted cells. We compared our present
TREC analysis results with those of a previous study
performed in our historical control double UCBT
patients treated with fludarabine, melphalan, and
ATG without PTH. Previous work from our group
in double UCBT recipients treated without PTH
demonstrated median TREC levels of 0 copies/mg
at 100 days after UCBT and 117 copies/mg at 6
months after UCBT. Patients who achieved
a TREC level of $2000 copies/mg DNA had better
survival [21]. Although the present study included
Biol Blood Marrow Transplant 18:1851-1858, 2012 1857Parathyroid Hormone and Cord Blood Transplantationonly a small number of patients, including patients
treated with both MAC and RIC regimens, TREC
reconstitution was more rapid than in our historical
controls, with an average of 365 copies/mg DNA at
100 days in the PTH group compared with 0 in the
historical control group and 819 copies/mg in the
PTH group compared with 74.9 copies/mg in the
no-PTH group at 6 months. These results are en-
couraging, given that higher TREC levels have
been correlated with lower TRM and improved sur-
vival. However, our study population had various op-
portunistic infections, including JC virus, respiratory
syncytial virus, and aspergillus. Two patients had cy-
tomegalovirus infection and 1 patient had Epstein-
Barr virus infection posttransplantation, similar to
our historical control population [9,10]. CD4
counts at day 1100 were higher in the PTH-
treated patients than in our historical control popula-
tion [9]. The small sample size of this study might
have prevented detection of any clinical benefit of im-
proved TREC levels or higher CD4 counts.
There are concerns about administration of PTH
to humans with malignancies, because of an increased
incidence of osteosarcoma in Fischer rats receiving
high doses of PTH. Intermittent administration of
PTH may induce chromosome and DNA breaks in
osteoblasts, but has not been associated with human
cancer [30]. In this study, with limited follow-up,
there was no evidence of secondary malignancies. In
this group of heavily pretreated patients, only 3 re-
lapses occurred, all in patients who received the
RIC regimen with ATG, and it is possible that the
use of ATG might have contributed to the relapses
occurring after RIC transplantation [31]. No relapses
occurred in the patients treated with the MAC regi-
men. This low incidence of relapse in our small co-
hort is encouraging, but the number of patients is
too small to definitively establish the safety of PTH
therapy after transplantation. In addition, there may
be a competing risk with early TRM; some of the pa-
tients receiving a MAC regimen died within the first
100 days and did not live long enough to relapse.
Further studies to address the potential effect of
PTH on the leukemia stem cell will involve patients
with acute myelogenous leukemia and chronic mye-
logenous leukemia undergoing standard, non-
transplantation treatment. Although we found no
improvement in hematopoiesis in this trial, it is pos-
sible that different approaches to stimulation of oste-
oblastic cells will be more effective and may warrant
further investigation.ACKNOWLEDGMENTS
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